The first hearing has taken place in the case against two lawyers accused of insider trading by the Financial Services Authority, marking the fifth criminal prosecution for insider trading brought by the regulatory body in the last 18 months.
Former Dorsey & Whitney corporate partner Andrew Rimmington and former McDermott Will & Emery partner Michael McFall – along with the former financial director of Neutec Pharma, Peter King – have been charged with insider dealing relating to Novartis’s 2006 takeover of Neutec.
